SINOPHARM(01099): China National Accord Medicines Corporation achieved a net profit attributable to shareholders of RMB 346 million in the third quarter, up 18.91% year on year.

Sinopharm Group (01099) announced that China National Accord Medicines Corporation achieved total operating revenue of approximately RMB 55.066 billion in the first three quarters of 2026, a year-on-year decrease of 0.11%; net profit attributable to shareholders of the listed company was approximately RMB 952 million, a year-on-year decrease of 0.48%; basic earnings per share were RMB 1.56. In the third quarter of 2026, operating revenue was RMB 18.800 billion, up 2.57% year on year; net profit attributable to shareholders of the listed company was RMB 346 million, up 18.91% year on year.